

## References

1. Sychov OS, Borodai AA, Borodai ES. Silent cerebral infarcts: definition, clinical consequences prognosis and its association with atrial fibrillation. *Arrhythmology* 2014;3(11):26–37.
2. Brott T, Tomsick T, Feinberg W, Johnson C, Biller J, Broderick J, Kelly M, Frey J, Schwartz S, Blum C. Baseline silent cerebral infarction in the Asymptomatic Carotid Atherosclerosis Study. *Stroke* 1994;25:1122–9.
3. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. *Health Technol Assess* 2007 Oct;11(38):iii-iv, ix-66.
4. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, Yan X, Mohanty S, Trivedi C, Bai R, Price J, Horton R, Gallingshouse GJ, Beheiry S, Zagrodzky J, Canby R, Leclercq JF, Halimi F, Scaglione M, Cesarani F, Faletti R, Sanchez J, Burkhardt JD, Natale A. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. *Heart Rhythm* 2014 May;11(5):791-8. doi: 10.1016/j.hrthm.2014.03.003. Epub 2014 Mar 4.
5. Ezekowitz M, James K, Davenport J, Broderick J, Gupta S, Thadani V, Meyer ML, Bridgers SL for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Silent Cerebral Infarction in Patients With Nonrheumatic Atrial Fibrillation. *Circulation* 1995;92:2178–82.
6. Ferguson G, Eliasziw M, Barr H, Clagett GP, Barnes RW, Wallace MC, Taylor DW, Haynes RB, Finan JW, Hachinski VC, Barnett HJ. Symptomatic Carotid Endarterectomy Trial Surgical Results in 1415 Patients for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators. *Stroke* 1999;30:1751–8.
7. Hara M, Ooie T, Yufu K, Tsunematsu Y, Kusakabe T, Ooga M, Saikawa T, Sakata T. Silent cortical strokes associated with atrial fibrillation. *Clin Cardiol* 1995;18:573–4.
8. Kleemann T, Becker T, Strauss M, Schneider S, Seidl K. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS<sub>2</sub> score. *Eur J Echocardiogr* 2009;10(3):383–8.
9. Lang R, Bierig M, Devereux R, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005;18:1440–63.
10. Lip GY, Kamath S, Jafri M. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. *Stroke* 2002;33:238–42.

11. Mearns E , White C, Kohn C, Hawthorne J, Song J-S, Meng J, Schein J, Raut M, Coleman C. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. *Thromb J* 2014;12:14. Published online Jun 24, 2014. doi: 10.1186/1477-9560-12-14.
12. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr* 2009;22(2):107–33.
13. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis. Health Quality Ontario. *Ont Health Technol Assess Ser* 2009;9(12):1–114.
14. Pollanen M, Deck J. The mechanism of embolic watershed infarction: experimental studies. *Can J Neurol Sci* 1990;17(4):395–8.
15. Russmann H, Vingerhoets F, Ghika J, Maeder P, Bogousslavsky J. Acute infarction limited to the lenticular nucleus: clinical, etiologic, and topographic features. *Arch Neurol* 2003 Mar;60(3):351–5.
16. Tangelder MJD, Algra A, Lawson JA, Hennekes S, Eikelboom BC. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. *J Vasc Surg* 2001;33:522–7.
17. Van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. *Chest* 2007 May;131(5):1508–15.
18. Wilson SJ-A, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. *Can Med Assoc J* 2003;169:293–8.